论文部分内容阅读
作者研究了居住在社区年龄65～85岁的男、女性居民用口服维生素D_3每4个月1次支持疗法对骨折和死亡率的影响。 方法 进行随机双盲对照试验,居住在普通社区居民2686名参加研究,男 2037、女649名,年龄65～85岁。排除已用过维生素D支持疗法和有维生素D疗法禁忌症(如肾结石、类肉瘤或恶性肿瘤)者。随机分为两组,分别口服维生素D_3(Cholecalciferol)100 000 IU或配对的安慰剂每4个月1次,连续5年(共15次口服)。于4年后检测了其中235名口服至少已10次的参与者的血清维生素D和甲状旁腺激素浓度。研究终点比较两组的骨折发病率和全因死亡率。
The authors studied the effects of 1-time supportive therapy with oral vitamin D_3 every 4 months on the incidence of fractures and death in male and female residents aged 65-85 years in the community. Methods A randomized, double-blind, controlled trial of 2686 residents living in ordinary communities participated in the study, with 2037 males and 649 females aged 65-85 years. Exclude those who have used vitamin D support therapy and vitamin D therapy contraindications (such as kidney stones, sarcoid or malignant tumors). The patients were randomly divided into two groups. Each group received 100 000 IU of vitamin D_3 (Cholecalciferol) or a placebo of paired patients once every 4 months for 5 consecutive years (15 times in total). Serum vitamin D and parathyroid hormone concentrations were tested in 4 of the 235 participants of whom 235 were orally administered at least 10 times. At the end of the study, fracture incidence and all-cause mortality were compared between the two groups.